Archives

by in
Entry Author Date Location
The Pharma Bureaucracy Index: Who’s Nimble, and Who’s Sloooowww? 09/30/13 National
Top 20 Under-the-Radar Trends in Innovation 05/30/13 National
San Diego Life Sciences Roundup: Optimer, Ambit, AnaptysBio, & More 05/17/13 San Diego
Boston Biotech Seizes the Momentum: Last Chance for Early Bird Tix 03/07/13 Boston
Someone Needs to Rank U.S. Biotech Hubs, For Real 03/04/13 National
RNA Therapeutics Are Coming of Age 02/08/13 San Diego
Who Are Biotech’s New Go-To Investment Bankers? 11/12/12 National
The Hepatitis C Market: Biotech’s Version of the Daytona 500 12/12/11 National
The Fall of Pfizer: How Big is Too Big for Pharma Innovation? 08/29/11 National
Regulus, the MicroRNA Child of Alnylam and Isis, Offers Litmus Test for Biotech Hope in 2011 02/07/11 San Diego
Top Trends to Watch in 2011 From Experts in Infotech, Biotech, Cleantech 01/19/11 National
John Mendlein Tries His Hand as a ‘Parallel Entrepreneur,’ Santaris Continues RNA Therapeutics Work for Pfizer, & More San Diego Life Sciences News 01/06/11 San Diego
Regulus Therapeutics, Spinoff of Isis and Alnylam, Forms $750M MicroRNA Deal With Sanofi 06/22/10 San Diego
Regulus, the MicroRNA Child of Isis and Alnylam, Strikes Potential $150M Deal with Glaxo 02/25/10 San Diego
Merck’s Alan Sachs, on RNAi’s Big Challenge: Delivery, Delivery, Delivery 01/21/10 National
Xconomy Forum: The Biotech Odyssey and Xconomy’s Ode to Innovation and Clean Air 12/15/09 San Diego
Nobel Laureate from Caltech, RNAi Leader To Headline Xconomy San Diego Event on Monday 12/09/09 San Diego
San Diego Biotech Leaders on the Future of Stem Cells, MicroRNA, & Cancer Biology 12/01/09 San Diego
Alnylam and Isis’ Offspring, Regulus, Keeps Pushing on Biology’s ‘Bleeding Edge’ 07/28/09 San Diego
Regulus Therapeutics Follows Through on Fundraising, Independence Plans 03/04/09 San Diego
Alnylam Looks to Spinoffs To Unleash RNAi Technologies for Stem Cells, Vaccines 02/18/09 Boston
Pfizer-Wyeth Combo’s Impact on San Diego Biotech: Bad for Dealmaking, Good for Shareholders 01/27/09 San Diego
Regulus, Leading Developer of MicroRNA Drugs, Prepares to Get Independence from Alnylam and Isis 01/21/09 San Diego
MicroRNA Leaps Ahead: Alnylam-Isis Venture, Regulus, Shows Its Drug Works in Animals With Heart Failure 11/30/08 San Diego
Sirtris Shifts Focus From Resveratrol, Merck Shifts People From Seattle to Boston, Epix Shifts Into Cost-Saving Mode, & More Boston-Area Life Sciences News 10/29/08 Boston
Page 1 of 1